ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer
Not Applicable
Completed
- Conditions
- Pancreas CancerPancreas Cyst
- Registration Number
- NCT04064034
- Lead Sponsor
- Mayo Clinic
- Brief Summary
Researchers have developed a new test to measure a protein QSOX1 that is found to be elevated in subjects with pancreas cancer. Researchers are looking to use this test to compare subjects with pancreas cancer and subjects without pancreas cancer to see if this test could be used to diagnosis pancreas cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Adult patients with biopsy-proven adenocarcinoma prior to receiving any therapy such as surgery, radiation or chemotherapy.
- Patients without pancreas cancer.
- Adult patients with benign pancreas disorders such as pancreatitis with imaging within 12 months (CT, MRI, EUS) documenting no cancer.
- Healthy adults with blood specimens in an existing biobank.
- Patients with pancreatic cystic lesions.
- Adult patients undergoing clinically indicated EUS-guided FNA biopsy of pancreatic cystic lesions.
Exclusion Criteria
- Prior treatment for pancreas cancer.
- Unable or unwilling to give consent.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Quiescin Sulfhydryl Oxidase 1 (QSOX1) in the blood Baseline Number of subjects with the presence and concentration of QSOX1 peptide found in the blood samples by the lateral flow assay (LFA) test
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic in Arizona
🇺🇸Scottsdale, Arizona, United States
Mayo Clinic in Arizona🇺🇸Scottsdale, Arizona, United States